drugset / Trial / NCT06958939
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Phase 1
Active not recruiting
10 enrolled
Ting Chang, MD
Hebei Senlang Biotechnology Inc., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This study is a single-center, open-label, single-arm, dose-exploration study to evaluate the safety and preliminary effectiveness of BCMA CAR-T（S103） in the treatment of refractory, generalized myasthenia gravis. The study is a dose escalation trial in adult, refractory, systemic MG patients. A total of 6-24 MG patients who meet the inclusion criteria are expected to be recruited.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2026-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S103 | Cell therapy | 1e+06 cells/kg | — |
| Subject | S103 | Cell therapy | 2e+06 cells/kg | — |
| Subject | S103 | Cell therapy | 4e+06 cells/kg | — |
| Subject | S103 | Cell therapy | 5e+06 cells/kg | — |